Apellis Pharmaceuticals, Inc.
Board Member
2026-03-01–present
Mikael Dolsten, M.D., Ph.D.
Board Member
Apellis Pharmaceuticals, Inc.
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Mikael Dolsten, M.D., Ph.D.
Mikael Dolsten, M.D., Ph.D. is recorded as Board Member at Apellis Pharmaceuticals, Inc.. Apellis Pharmaceuticals, Inc. reported in an 8-K filed March 2, 2026 that Mikael Dolsten, M.D., Ph.D. was appointed Class I director, effective March 1, 2026.
“On February 27, 2026, the Board of Directors (the "Board") of Apellis Pharmaceuticals, Inc. (the "Company"), upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Mikael Dolsten, M.D., Ph.D., to the Board as a Class I director, effective as of March 1, 2026, to serve until the Annual Meeting of Stockholders to be held in 2027 or until his successor has been duly elected and qualified or until his earlier death, resignation or removal.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Apellis Pharmaceuticals, Inc.
Board Member
SEC 8-K
Current2026-03-01–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.